ERS Genomics stands as the global leader in CRISPR/Cas9 licensing, uniquely positioned at the intersection of cutting-edge science, commercial accessibility, and responsible innovation.
Our approach to licensing, evidenced by over 145 licenses already granted worldwide, proves that sophisticated IP management can accelerate rather than hinder scientific progress and support groundbreaking innovation. This approach has broken down traditional barriers to entry, enabling organisations of all sizes to responsibly access and participate in the CRISPR biotech revolution.
Based on Emmanuelle Charpentier’s & Jennifer Doudna’s Nobel Prize winning discovery of how CRISPR/Cas9works, and the transformational impact it had as the gold standard method for gene editing, ERS Genomics licenses worldwide access to the essential CVC CRISPR/Cas9 patent portfolio. This portfolio includes over 100 patents granted worldwide covering the fundamental uses of CRISPR/Cas9 technology across all cells—bacteria, archaea, yeasts, algae, animals, and more. By partnering with innovators and helping them to navigate the complex landscape of CRISPR/Cas9, ERS Genomics empowers companies to innovate freely and confidently develop, manufacture, and bring to market products and services that leverage this transformational technology.
ERS Genomics has successfully collaborated with companies across the pharma, biotech, life sciences, and other industries, providing licenses that support rapid time-to-market for CRISPR-based products and services. In the biotech and pharmaceutical sectors, our licensees are transforming drug discovery by streamlining the identification of new drug targets, refining disease models, and addressing drug resistance. In particular, high-throughput genetic screening enabled by CRISPR/Cas9 accelerates therapeutic development, advancing pharmaceutical pipelines with unprecedented efficiency. Beyond these industries, CRISPR/Cas9 is driving innovation in fields like agriculture, cultured meat, and sustainable biofuels, where our licensees are engineering solutions for a better future.
As CRISPR applications expand—from agricultural breakthroughs to synthetic biology—ERS Genomics plays a critical role in ensuring that companies across diverse industries can harness the transformative potential of CRISPR/Cas9. Our ability to balance broad accessibility with a robust IP position offers a model for the commercialisation of future scientific breakthroughs, demonstrating how transformative technologies can be both protected and widely accessible for global impact, catalysing innovation.
At the heart of our mission is providing simple, clear access to CRISPR/Cas9, allowing companies to focus on what truly matters: developing life-changing treatments and technologies.
If you’re attending BIO-Europe in Stockholm this November and would like to explore collaboration opportunities, we’d love to connect. Reach out to our team—we’re eager to engage and help unlock new avenues for innovation and competitive advantage in an evolving market.
John E. Milad
CEO, ERS Genomics